Tazobac IV Infusion
Piperacillin + Tazobactam
4g + 0.50g
ACI Limited
| Pack size | 1's Pack |
|---|---|
| Unite Price | 1003.01 BDT |
Indications
Tazobac IV Infusion is used for:
Septicaemia, Nosocomial pneumonia
Adult Dose
Intravenous
Nosocomial pneumonia
Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min. When used empirically, combination w/ aminoglycoside or antipseudomonal fluoroquinolone is recommended.
Empiric therapy for febrile neutropenic patients
Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min.
Complicated intra-abdominal infections
Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min.
Complicated urinary tract infections; Skin and soft tissue infections
Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min.
Child Dose
Intravenous
Child: Usually <40 kg: 240–300 mg PIP/kg/day 8 hourly
Alternatively
Nosocomial pneumonia
Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min.
Max: 4.5 g per dose; >12 yr Same as adult dose.
Empiric therapy for febrile neutropenic patients
Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min.
Max: 4.5 g per dose; >12 yr Same as adult dose.
Complicated intra-abdominal infections
Child: 2-12 yr 112.5 mg/kg (piperacillin 100 mg and tazobactam 12.5 mg) 8 hrly for 5-14 days by infusion over 30 min.
Max: 4.5 g per dose.
Renal Dose
Renal impairment: Haemodialysis patients: 2.25 g 12 hrly; additional dose of 0.75 g after each dialysis session. CAPD: 2.25 g 12 hrly.
CrCl (ml/min) Dosage Recommendation
<20 2.25 g 8 hrly.
20-40 2.25 g 6 hrly.
Administration
Reconstitution
Reconstitute initially (2.25 g in 10 mL, 4.5 g in 20 mL) w/ water for inj, glucose 5% or NaCl 0.9%, then further dilute to 50-150 mL w/ compatible infusion soln.
IV Administration
Infusion over 30 min
Contra Indications
Hypersensitivity.
Precautions
Pregnancy and lactation, pseudomembranous colitis. Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients with low K reserves. Increased risk of fever and rash in patients with cystic fibrosis. Increased risk of bleeding manifestations. Prolonged treatment may increase risk of superinfections. Convulsions or neuromuscular excitability may occur when high doses are used, especially in renally impaired patients. Renal impairment.
Lactation: Low concentrations of piperacillin excreted in breast milk; tazobactam unknown; use caution
Pregnancy-Lactation
Pregnancy
Piperacillin and tazobactam cross placenta in humans; however, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage
Animal data
No fetal structural abnormalities observed in rats or mice when drug administered intravenously during organogenesis at doses 1 to 2 times and 2 to 3 times human dose of piperacillin and tazobactam, respectively; based on body-surface area (mg/m2); however, fetotoxicity in presence of maternal toxicity was observed in developmental toxicity and peri/postnatal studies conducted in rats (intraperitoneal administration prior to mating and throughout gestation or from gestation day 17 through lactation day 21) at doses < maximum recommended human daily dose based on body-surface area (mg/ m²)
Lactation
Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been Studied; no information available on effects of piperacillin and tazobactam on breastfed child or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for drug and any potential adverse effects on breastfed child from therapy or from underlying maternal condition
Interactions
Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.
Side Effects
Side effects of Piperacillin + Tazobactam :
>10%
Diarrhea (7-11%)
1-10%
Constipation (1-8%), Headache (1-8%), Insomnia (4-7%), Nausea (2-7%), Fever (2-5%), Oral candidiasis (2-4%), Rash (2-4%), Vomiting (2-4%), Dyspepsia (3%), Pruritus (3%), Pain (2-3%), Hypertension (2%), Leukopenia (1%), Thrombocytopenia (1.4%)
<1%
Anaphylaxis, Agranulocytosis, Thrombocytopenia, Eosinophilia, Leukopenia, Positive Coombs test, Prolonged PT and PTT, Transient LFT and creatinine elevations.Seizure, Pulmonary edema, Pulmonary embolism
Mode of Action
Piperacillin has an antimicrobial activity against a wide range of gm-ve organisms including K. pneumoniae, P. aeruginosa, Enterobacteriaceae and against gm+ve organisms eg E. faecalis and B. fragilis. Tazobactam is a penicillanic acid sulfone derivative with beta-lactamase inhibitory properties. In combination, tazobactam enhances the activity of piperacillin against beta-lactamase-producing bacteria.
Note
Tazobac 4g + 0.50g IV Infusion generic name is Piperacillin + Tazobactam. Tazobac 4g + 0.50g IV Infusion is manufactured by ACI LimitedTazobac is availble in all over Bangladesh.
Mes BD drug index information on Tazobac IV Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.